On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Blockbuster Year and Bright Horizons for SPACs

NetworkNewsWire Editorial Coverage: The year 2020 has already seen 127 SPAC IPOs, which have collectively raised over $48.5 billion in proceeds — more than the past ten years combined. A special purpose acquisition company (SPAC) is essentially a blank-check company formed to raise capital through an IPO with the sole intent of buying or merging with another operating company. SPACs have evolved to become an expedited and cost-effective way of doing an M&A deal and have been utilized by multiple Wall Street heavyweights. Going public via a SPAC enables a company to get a deal done in weeks instead of months, and the approach is proving to be an especially attractive vehicle for biotech companies by providing ready access to capital and much greater public visibility. A successful biotech SPAC hinges on shrewd management and a target company that offers a strong risk/reward proposition, is focused on unmet medical needs, and has proven scientific and clinical leadership. After  evaluating over 50 companies to meet these criteria for success, KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC), entered into a definitive merger agreement with 180 Life Sciences Corp. (180 Profile), which is expected to close within one month. 180 Life Sciences represents a new business model in biotech. The company is founded and run by four world-renowned scientists and entrepreneurs who invested their own money to start the company. Of considerable note: the founders own the majority of the equity in 180 Life Sciences and aren’t selling any in this transaction. Immatics N.V. (NASDAQ: IMTX) received proceeds of around $250 million in a biotech SPAC business combination. Immunovant Inc. (NASDAQ: IMVT), a biopharmaceutical company, went public via a SPAC business merger, and four months later, the company was able to raise $134 million in a new public offering. AdaptHealth Corp. (NASDAQ: AHCO), the third-largest distributor of home medical equipment in the United States, also went public via a SPAC business merger in July and has appreciated 50% since. After raising $1.1 billion, a business combination is expected this month between Churchill Capital Corp III (NYSE: CCXX) and MultiPlan Inc., a market leader in health-care cost-management solutions. It’s already been a heck of a year for SPACs, and some say the best is yet to come.

  • SPACs offer new method for IPOs and M&As.
  • SPACs have attracted big names and big money.
  • SPACs work well for biotech — quick access to capital and high visibility.
  • 180 Life Sciences Corp. is anticipated to merge before year end, expectations high for success.

SPAC Attack

The flurry of SPACs this year is a reaction to a multiplicity of long simmering factors. The traditional IPO process is inherently costly, cumbersome and risky. Most companies follow the traditional IPO process, but it’s an expensive and extensive process. After months of negotiations, due diligence and road shows — bankers price the IPO and then a block of shares are sold at the set price to institutional investors — not everyone ends up pleased with either the pricing or the process.

It only took a few high-profile SPACs led by big names to show investors and companies that there are faster and simpler ways to go public other than a conventional IPO, especially during these uncertain times of COVID-19. SPACs are proving to be a good option for companies looking to go public, especially in the biotech arena. SPACs allow companies to get financed and reach the public market quicker. SPACs have also traded well, many delivering outsized returns, bolstering both investor confidence and demand.

Perfect Target

KBL Merger Corp. IV is the fourth SPAC run by CEO Marlene Krauss, MD. She’s a pioneer in the field, completing her first SPAC in 1998, and is a member of an elite group of only three women, including herself, who have served in the capacity of SPAC CEO and chairperson. She was also one of the first people to obtain both an MD degree and MBA degree from Harvard, and she’s one of the few physicians to lead a SPAC. Through her unique combination of intimate knowledge and shrewd experience, she was able to find and fund Summit Autonomous Inc., which manufactures Summit Technology excimer laser, the first laser to be approved by the FDA for LASIK refractive eye surgery. The advent of LASIK created a new industry and a much-improved standard of care. Summit, now a subsidiary of Novartis, was sold to Alcon for $893 million. Krauss’s devotion to improving lives by improving health-care solutions has led to the transaction with 180LS. Krauss and her team closely evaluated and discarded more than a dozen companies before finally selecting 180LS to merge with KBLM.

That company — 180 Life Sciences Corp.  — was started by four world-renowned scientists and entrepreneurs who invested their own money to start the company. These same distinguished biomedical pioneers were the first to successfully develop new anti-inflammatory drugs in the late ‘90’s, drugs such as the anti-TNF biologics and the anti-integrin inhibitors. These drugs are still on the market, generating multiple billions of dollars per year in sales; in addition, they have spawned a new class of therapeutics to treat inflammation. The talent and genius at 180 Life Sciences is now focused on creating the next generation of innovative anti-inflammatory drugs to inhibit the ravages of chronic inflammation and provide relief for millions of patients with inflammatory disease.

Expectations are high for 180 Life Sciences (180LS) since the founders have all succeeded at this before: developing large-market novel drugs that were sold to big pharma for multiple billions of dollars. Now they’re aspiring to do it again — but in their own unique way. They’ve minimized both the risk and the cost typically associated with biotechnology by creating a collaborative system of basic science and clinical trials conducted simultaneously at three major universities across the globe: Stanford University, Hebrew University and Oxford University. The international collaboration between this cadre of scientific luminaries and the effective sharing of programs and platforms developed through decades of research and clinical development has resulted in the creation of 180LS with three drug platforms at various stages of clinical development.

The company’s primary targets are fibrosis and inflammation using anti-TNF therapy, which suppresses the immune system by blocking the activity of a substance in the body that can cause inflammation and lead to immune-system diseases. The Fibrosis & Anti-TNF program based at Oxford University is completing phase 2b/3. This program is led by Jagdeep Nanchahal, a surgeon-scientist running the phase 2 trials, and Marc Feldmann, a world-renowned immunologist and a pioneer of anti-TNF therapy. Preclinical studies in liver fibrosis and nonalcoholic steatohepatitis (NASH) are set to begin in late 2020. Two additional clinical programs are projected to start Q3/4 2021 with a grant awarded by the UK’s National Institute for Health Research.

The other two preclinical programs are Inflammatory Pain, directed by Raphael Mechoulam at the Hebrew University in Israel, which is focused on discovering novel compounds to treat chronic inflammatory pain; and A7nAChR, which is led by Lawrence Steinman and Jonathan Rothbard, MD, seeking to develop a treatment for ulcerative colitis in ex-smokers by targeting the a7nAChR, a nicotine receptor in the body and a central factor in the body’s method of controlling inflammation. James N. Woody, MD, PhD, is CEO of 180LS and was instrumental in the discovery of Remicade, the first anti-TNF blockbuster, as chief scientific officer at Centocor. Woody previously founded Avidia and Proteolix, both of which were subsequently sold to Amgen, and also served as general manager of Roche Biosciences, the former Syntex Pharmaceutical Company.

This unique global collaboration of scientific pioneers and biomedical entrepreneurs mitigates costs and risks while maximizing opportunities for 180LS. The team’s cumulative experience, acumen and respect from big pharma enhances opportunities for developing drugs to commercialization as well as increased opportunities for licensing and joint ventures.

Bringing Opportunity to Fruition

It’s often said that opportunity and convenience seldom walk hand in hand. In fact, to bring opportunity to fruition is never convenient — it requires hard work, intelligence and diligence. Due to the vision and diligence of Krauss, 180 Life Sciences is slated to merge with KBL Merger Corp. IV soon, obtaining capital to press its mission to completion. This is an opportunity to potentially affect the trajectory of treatment protocols for millions of patients with untreatable inflammatory disease and these vast unmet medical needs may soon have new solutions created from the hard work and the brilliance of the collaborative team at 180 Life Science. For investors, it’s also an opportunity to participate in what may become a potential blockbuster drug spawned from a SPAC. It’s been a heck of a year, and the best may be on the horizon.

SPAC Success

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, went public through a business combination with Arya Sciences Acquisition Corp., a SPAC sponsored by Perceptive Advisors. Proceeds from the transaction were approximately $250 million. Immatics is developing targeted immunotherapy candidates based on its suite of technologies that enables the identification of otherwise inaccessible intracellular protein targets displayed on the cell’s surface. Accessing these targets is generally recognized as an important key to unlocking hard-to-treat cancers.

Immunovant Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, went public via a SPAC business merger in December 2019. Once public, the company was able to raise $134 million in a public offering priced at $14.50 a share, and the stock just hit $38.50. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. The company just announced closing of a $200 million public offering.

AdaptHealth Corp. (NASDAQ: AHCO), the third-largest distributor of home medical equipment in the country, also went public via a business combination with DFB Healthcare Acquisitions Corp., a special purpose acquisition company. The combined company represented an initial enterprise value of approximately $1 billion and market capitalization of approximately $800 million. AdaptHealth offers a full suite of medical products for both rental and sale, with a focus on respiratory and/or mobility equipment, including CPAP sleep equipment, oxygen equipment, wheelchairs, walkers and hospital beds. The company has created a scalable, purpose-built, and centralized operating platform that optimizes client service and delivery, improves compliance, drives operational and financial efficiencies, and increases enterprise-wide profitability.

After raising $1.1 billion, a business combination is expected on October 8, 2020, between Churchill Capital Corp III (NYSE: CCXX) and MultiPlan Inc., a market leader in health-care cost-management solutions and a trusted partner to over 700 health-care payers in the commercial health, dental, government and property and casualty markets. MultiPlan interprets clients’ needs and customizes innovative solutions that combine its payment integrity, network-based and analytics-based services. Churchill Capital Corp III is a public investment vehicle formed for the purpose of effecting a merger, acquisition, or similar business combination. Churchill III was founded by a group of leading current and former business and financial leaders.

This year may well be remembered as the year of the SPAC, representing a new paradigm in IPOs and M&A transactions. If past is prologue, expect even more SPACs in years to come. The ready access to capital and speed to public markets make SPACs attractive vehicles, especially for biotech companies such as 180 Life Sciences.

For more information about 180 Life Sciences Corp., please visit 180 Life Sciences Corp. and see the 180 Life Sciences company presentation.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Additional Information about the 180 Life Sciences Business Combination and Where to Find It

KBL Merger Corp. IV (“KBL”) has filed a registration statement on Form S-4, which includes a preliminary proxy statement/prospectus for KBL’s stockholders, with the Securities and Exchange Commission. KBL’s definitive proxy statement/prospectus will be mailed to KBL’s stockholders that do not opt to receive the document electronically. KBL and 180 Life Sciences urge investors, stockholders and other interested persons to read the preliminary proxy statement/prospectus, as well as other documents that will be filed with the SEC, because these documents will contain important information about the proposed business combination transaction. Such persons can also read KBL’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, for a description of the security holdings of its officers and directors and their respective interests as security holders in the consummation of the proposed business combination transaction. KBL’s definitive proxy statement/prospectus, which is included in the registration statement, will be mailed to stockholders of KBL as of a record date to be established. KBL’s stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: KBL Merger Corp. IV, 30 Park Place, Suite 45E, New York, NY 10007; e-mail: admin@kblvc.com  These documents can also be obtained, without charge, at the SEC’s web site (http://www.sec.gov)

Participants in Solicitation

KBL and its directors and executive officers may be deemed to be participants in the solicitation of proxies for the special meeting of KBL’s stockholders to be held to approve the proposed transactions in connection with the business combination with 180 Life Sciences. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of KBL’s stockholders in connection with the proposed business combination with 180 Life Sciences are set forth in the amended preliminary proxy statement/prospectus included in the registration statement that was filed with the SEC on August 28, 2020. You can find information about KBL’s executive officers and directors in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on April 7, 2020. You can obtain free copies of these documents from KBL using the contact information above.


This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination between KBL and 180 Life Sciences and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of KBL and 180 Life Sciences, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217